Aurinia Shareholder Urges Strategic Review, Company Sale
Activist investor MKT Capital issued a letter to shareholders of Canadian biotech Aurinia Pharmaceuticals Inc. on Monday, urging Aurinia to begin a strategic review process with a reconstituted board and explore...To view the full article, register now.
Already a subscriber? Click here to view full article